Analyst Price Target is $61.33
▲ +25.55% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Janux Therapeutics in the last 3 months. The average price target is $61.33, with a high forecast of $100.00 and a low forecast of $35.00. The average price target represents a 25.55% upside from the last price of $48.85.
Current Consensus is
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Janux Therapeutics. This Buy consensus rating has held steady for over two years.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More
